Levosimendan
Top View
- Dobutamine Versus Levosimendan for Patients with Acute Decompensated Heart Failure
- (12) United States Patent (Io) Patent No.: US 9,526,824 B2 Ferrari Et Al
- Acute Heart Failure: Early Pharmacological Therapy
- Inodilators in Septic Shock: Should These Be Used?
- ATC-Index Mit DDD-Angaben Für Den Deutschen Arzneimittelmarkt Berlin 2013, 12
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- A Comparison of Haemodynamic Effects and Safety Between Domestic Levosimendan Versus Dobutamine for Hospitalized Patients with A
- Wo 2007/044693 A2
- Levosimendan, Vasopressin, Terlipressin Theory Vs Reality
- Comparison of Levosimendan Vs. Milrinone in Pediatric Cardiac Surgery
- Harmonized Tariff Schedule of the United States (2006) (Rev
- Comprehensive Comparisons Among Inotropic Agents on Mortality and Risk of Renal Dysfunction in Patients Who Underwent Cardiac Su
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Intravenous Levosimendan and Vasopressin in New- Onset Acute Pulmonary Hypertension After Weaning from Cardiopulmonary Bypass
- The Effects of Levosimendan and Dobutamine in Experimental
- NEW ZEALAND DATA SHEET 1. SIMDAX 2.5Mg/Ml Injection Concentrate
- (12) United States Patent (10) Patent No.: US 8,480,637 B2 Ferrari Et Al
- Current Real-Life Use of Vasopressors and Inotropes in Cardiogenic Shock